Alnylam Pharmace. buy Evercore ISI
Start price
25.06.24
/
50%
€221.10
Target price
25.06.25
€242.92
Performance (%)
7.69%
Price
10.07.24
€238.10
Summary
This prediction is currently active. With a performance of 7.69%, the BUY prediction by Evercore_ISI for Alnylam Pharmace. is trending in the right direction. This prediction currently runs until 25.06.25. The prediction end date can be changed by Evercore_ISI at any time. Evercore_ISI has 50% into this predictionAlnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.
Performance without dividends (%)
| Name | 1w |
|---|---|
| Alnylam Pharmace. | 3.522% |
| iShares Core DAX® | 0.326% |
| iShares Nasdaq 100 | 2.022% |
| iShares Nikkei 225® | 3.677% |
| iShares S&P 500 | 1.405% |
Comments by Evercore_ISI for this prediction
In the thread Alnylam Pharmace. diskutieren
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its price target raised by analysts at Evercore ISI from $210.00 to $260.00. They now have an "outperform" rating on the stock.
Ratings data for ALNY provided by MarketBeat